We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ORNBV:OMXHEXOrion Oyj Class B Analysis

Data as of 2026-07-08 - not real-time

€67.88

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Orion Oyj is trading at its technical support of €67.88, just below the 20‑day (68.83) and 50‑day (69.16) simple moving averages, suggesting short‑term pressure. The RSI of 23 places the stock in oversold territory, while the MACD histogram remains negative, indicating lingering bearish momentum. Volume has been decreasing, and the market’s beta of 0.19 points to very low systematic risk, though the 30‑day volatility of roughly 16% adds a modest price swing component. Fundamentally, the company boasts an impressive ROE of 48% and operating margin of 27%, far outpacing many peers, and its PE ratio of 18 is well below the industry average of 29, signaling relative valuation attractiveness. However, the discounted cash‑flow model estimates a fair value near €63, which is lower than the current price, implying a slight overvaluation on intrinsic grounds. The dividend remains attractive at 2.65% with a payout ratio under 50%, supported by solid free cash flow and a manageable net‑debt position. Overall, the stock sits at a crossroads where technical weakness meets strong fundamentals and a defensive, low‑beta profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price at technical support with oversold RSI
  • Bearish MACD signal and decreasing volume
  • Very low beta limiting market‑wide shocks

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong profitability metrics (ROE 48%, operating margin 27%)
  • Attractive PE relative to industry peers
  • Sustainable dividend yield with healthy payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust cash generation and manageable debt levels
  • Defensive healthcare exposure with diversified product portfolio
  • Low systematic risk combined with consistent dividend policy

Key Metrics & Analysis

Financial Health

Revenue Growth17.80%
Profit Margin27.11%
P/E Ratio18.1
ROE48.37%
ROA22.11%
Debt/Equity29.43
P/B Ratio8.5
Op. Cash Flow€276.4M
Free Cash Flow€328.3M
Industry P/E29.3

Technical Analysis

TrendNeutral
RSI23.1
Support€67.88
Resistance€71.68
MA 20€68.83
MA 50€69.16
MA 200€66.66
MACDBearish
VolumeDecreasing
Fear & Greed Index91.34

Valuation

Fair Value€62.99
GradeFair
TypeBlend
Dividend Yield2.65%

Risk Assessment

Beta0.19
Volatility15.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.